

1 **Title: Resistin in obese subcutaneous adipose tissue impairs human skeletal**
2 **muscle myogenesis by activation of the NFκB pathway**

3 Mary F. O'Leary¹, Graham R. Wallace¹, Edward T Davis², Andrew J. Bennett³,
4 Kostas Tsintzas⁴, Simon W. Jones^{1*}

5

6 ¹Institute of Inflammation and Ageing, MRC-ARUK Centre for Musculoskeletal
7 Ageing Research, University of Birmingham, Birmingham, UK

8 ²The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South,
9 Northfield, Birmingham, B31 2AP, UK.

10 ³FRAME Alternatives Laboratory, School of Life Sciences, Faculty of Medicine &
11 Health Sciences, University of Nottingham, Nottingham, UK

12 ⁴MRC-ARUK Centre for Musculoskeletal Ageing Research, School of Life Sciences,
13 Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK

14

15 ** Corresponding author and person to whom reprint requests should be addressed:*

16 Simon W. Jones, MRC-ARK Centre for Musculoskeletal Ageing Research,
17 University of Birmingham, Birmingham B15 2TT, UK.

18 E-mail: s.w.jones@bham.ac.uk.

19

20 **Word count:**

21 **Key words:** Sarcopenia, myogenesis, resistin, obesity, adipokines.

22 **Short title:** Resistin and human myogenesis

23 **Abstract**

24 Adipokines have been implicated in the loss of skeletal muscle mass with age and in
25 several chronic disease states, particularly in overweight individuals. The aim of this
26 study was to determine the effects of human obese and lean subcutaneous adipose
27 tissue secretome on myogenesis and metabolism in skeletal muscle cells derived from
28 both young (18-30 yr) and elderly (> 65 yr) individuals. These effects were determined
29 by quantifying myotube thickness and nuclear fusion index along with indices of
30 mitochondrial function, intracellular lipid content and signalling pathways.

31 Obese subcutaneous adipose tissue secretome, generated by conditioned media,
32 impaired the myogenesis of old myoblast cultures but had no significant effect on
33 young myoblasts. Resistin was identified as an adipokine that is prolifically secreted
34 by obese subcutaneous adipose tissue and this adipokine was chosen for further
35 study. Stimulation of old myoblasts with resistin impaired both myotube thickness and
36 nuclear fusion. Stimulation of young myoblasts with resistin impaired myotube
37 thickness, but had no effect on the number of nuclei incorporated into myotubes.
38 Depletion of resistin from obese adipose tissue secretome restored myogenesis.
39 Inhibition of the classical NFκB pathway protected myoblasts from the detrimental
40 effect of resistin on myogenesis. Resistin also increased myotube respiration, ATP
41 production and proton leak, promoted intramyocellular lipid accumulation and
42 enhanced fatty acid oxidation by myotubes.

43 In conclusion, resistin derived from human obese subcutaneous adipose tissue
44 impairs myogenesis of human skeletal muscle, particularly older muscle, and alters
45 muscle metabolism in developing myotubes. These findings may have important
46 implications for the maintenance of muscle mass and metabolic control in older people
47 with chronic inflammatory conditions, or older people who are obese or overweight.

48

49 **Introduction**

50 The loss of skeletal muscle mass with ageing (sarcopenia) is accompanied by an
51 increased systemic inflammatory burden (Himmerich, et al. 2006) and accumulation
52 of adipose tissue (Kyle, et al. 2001), which is known to be a prolific secretor of pro-
53 inflammatory cytokines (Lehr, et al. 2012) termed adipokines. Notably, the prevalence
54 of sarcopenia is greater in obese than in non-obese older individuals (Srikanthan, et
55 al. 2010) and this association has been referred to as sarcopenic obesity (Stenholm,
56 et al. 2008). Sarcopenic obesity is considered to be an important public health concern
57 in the elderly as it confers a higher risk for developing disability in the muscle functional
58 activities of daily living, culminating in reduced quality of life (Baumgartner, et al. 2004).
59 Significantly, sarcopenic obesity is associated with increased levels of systemic pro-
60 inflammatory markers after adjusting for the presence of other pro-inflammatory states
61 such diabetes and cancer (Batsis, et al. 2016).

62

63 Cross-sectional studies of the body composition of individuals across the lifespan
64 found that total adipose tissue mass (Schutz, et al. 2012) and visceral adipose tissue
65 (VAT) mass (Yamada, et al. 2014) negatively correlated with skeletal muscle mass.
66 Indeed, the cross-sectional Health, Aging, and Body Composition (Health ABC) study
67 of 3075 men and women aged 70–79 years demonstrated that those with high
68 systemic concentrations of TNF α and IL-6 had a smaller mid-thigh muscle cross-
69 sectional area and decreased grip strength (Visser, et al. 2002). Furthermore,
70 circulatory levels of adiponectin and resistin are increased in old individuals, compared
71 to the young, and are inversely associated with muscle strength (Bucci, et al. 2013).
72 Collectively, these studies indicate that sarcopenia is – in part – an adipokine-driven
73 phenomenon. Indeed, increased adipocyte-derived pro-inflammatory cytokines and
74 lipid metabolites may contribute to decreased regenerative capacity (Akhmedov and

75 Berdeaux 2013) and myogenesis (Takegahara, et al. 2014) of skeletal muscle.
76 However, although the anti-myogenic and muscle atrophic actions of some adipokines
77 (such as TNF α and IL-6) are well studied in this respect (Adams, et al. 2008; Garcia-
78 Martinez, et al. 1993; Garcia-Martinez, et al. 1994; Haddad, et al. 2005; Tsujinaka, et
79 al. 1995; Tsujinaka, et al. 1996), the functional effects of many other obesity-
80 associated adipokines, including resistin, on human skeletal muscle are not well
81 characterised. Furthermore, very few studies have examined the inflammatory milieu
82 secreted by human subcutaneous adipose tissue (SAT).

83 Despite the prominent attention that visceral adipose tissue (VAT) has received as a
84 secretor of adipokines, SAT also secretes pro-inflammatory adipokines, albeit to a
85 lesser extent (Blaber, et al. 2012; Pellegrinelli, et al. 2015; Skurk, et al. 2007).
86 Importantly, SAT represents a much greater proportion of total adipose tissue mass
87 than VAT (Isaac, et al. 2011; Rosqvist, et al. 2017; Rossi, et al. 2011), and therefore
88 may be greatly underappreciated as a contributor to the systemic inflammatory
89 burden. To our knowledge, a single study has directly examined the effect of an
90 inflammatory milieu secreted by human SAT adipocytes on primary human myotube
91 morphology (Pellegrinelli et al. 2015). This particular study showed that conditioned
92 medium from SAT adipocytes derived from lean individuals does not alter the MTT or
93 NFI of myotubes in myogenic cultures isolated from a neonate (Pellegrinelli et al.
94 2015). Interestingly, adipocytes isolated from obese SAT showed an intermediary
95 inflammatory profile and negative effect on MTT between lean SAT and obese VAT. In
96 the same study, conditioned medium from obese VAT adipocytes significantly
97 diminished MTT but not NFI when compared with control and lean SAT. Furthermore,
98 direct co-culture of obese VAT adipocytes with myoblasts derived from a neonate,
99 resulted in significant reduction in the expression of the myogenic transcription factors

100 MyoD1 and myogenin. However, the study used adipocytes, rather than whole adipose
101 tissue to generate conditioned medium representing the secretome, and thus did not
102 characterise the effects of adipose tissue's complete inflammatory milieu on myogenic
103 cultures. Critically, the stromal vascular fraction of adipose tissue, which includes
104 preadipocytes and macrophages, is a more prolific secretor of pro-inflammatory
105 cytokines than mature adipocytes (Blaber et al. 2012). Furthermore, the myotubes
106 used were neonate not from adult donors. Consequently, adipokine secretion by
107 human adipose tissue – not just that by adipocytes – must be characterised and its
108 effect on human myofibre size and function determined.

109 The aim of this study was therefore to determine the effects of lean and obese SAT
110 conditioned media secretome, and in particular the adipokine resistin, concentrations
111 of which are known to be increased in the serum of obese individuals (Jonas, et al.
112 2017; Philp, et al. 2017), on human skeletal muscle myogenesis using muscle cell
113 cultures derived from both old and young individuals.

114

115

116 **Materials and Methods**

117 **Skeletal muscle biopsy and myogenic culture isolation**

118 Three young healthy subjects (2 males and 1 female; age 24.4 ± 1.5 yr; BMI $22.6 \pm$
119 2.2 kg/m²) and four elderly healthy individuals (2 males and 2 females; age 70.5 ± 2.8 ;
120 BMI 21.8 ± 1.3 kg/m²) were recruited and gave written informed consent. All
121 participants were physically active (at least 150 minutes of self-reported moderate
122 intensity activity per week). Participants were free from cardiovascular, metabolic,
123 neuromuscular or other diseases that might affect muscle growth and metabolism
124 during screening. The study was approved by the University of Nottingham Medical
125 School Ethics Committee (G11092014SoLS) and was conducted in accordance with
126 the guidelines of the Declaration of Helsinki. A vastus lateralis muscle biopsy was
127 obtained from each subject and the satellite cell population extracted as previously
128 described (O'Leary, et al. 2017). Our isolation technique has consistently generated
129 cultures in our laboratories that produce desmin positive multinucleated myotubes that
130 are negative for the fibroblast marker TE7 (O'Leary et al. 2017). Additionally,
131 commercially available primary human myoblasts (Thermo Fisher cat. No. A12555),
132 isolated from a female aged 21 yr were used for the mechanistic studies presented in
133 Figures 3-6. They were cultured in the same media and conditions as the cultures that
134 we isolated in-house.

135

136 **Generation of adipose conditioned medium secretome**

137 Following ethical approval (UK National Research Ethics Committee 16/SS/0172),
138 SAT was obtained intraoperatively from $n = 13$ lean (BMI <25 , age 68.1 ± 3.3 years)
139 and $n = 22$ non-lean (BMI >25 , age 69.5 ± 1.8 years) older individuals undergoing
140 elective total joint replacement surgery at either the Royal Orthopaedic Hospital

141 (Birmingham, UK) or Russell's Hall Hospital (Dudley,UK). SAT was incubated in
142 myotube differentiation medium at a ratio of 1 g tissue to 10 mL medium for 24 h at 37
143 °C, 21 % O₂ and 5 % CO₂. Larger samples were divided into segments of ~ 1 g to
144 ensure that the surface area of adipose tissue exposed to medium remained
145 approximately constant. At 24 h the adipose conditioned medium (ACM) was removed,
146 aliquoted into 5 mL sample containers and stored at - 80 °C. For experimental use,
147 the ACM was diluted 1:2 with differentiation medium, to ensure a sufficient nutrient
148 composition to sustain myogenic differentiation.

149

150 **Immunofluorescence staining**

151 Myotubes were differentiated for 8 d in the presence of ACM secretome or
152 recombinant resistin protein. The details of cytokine concentrations, as well as the
153 timing and duration of such stimulations, are described in the relevant results section
154 and Figure legend. Media were renewed every 2 d. The culture medium was removed
155 and the cells fixed with 2% formaldehyde in PBS for 30 min. Following
156 permeabilization in 100% methanol for 10 min, wells were blocked with 5% goat serum
157 in PBS for 30 min. The primary antibody was diluted (Desmin, 1:1000, Dako) in 1%
158 BSA/PBS and 150 µL was added per well for 1 hour. Wells were subsequently
159 incubated with 150 µL/well secondary antibody (Goat anti-Mouse IgG (H+L), Alexa
160 Fluor® 488 conjugated, Thermo Fisher) for 1 h in the dark. Each well was washed with
161 PBS and 150 µL/well DAPI/PBS (1:5000, Cell Signalling Technology) was added for
162 5 min in the dark. Wells were further washed with PBS, a drop of mountant added to
163 each well (ProLong Diamond Antifade, Thermo Fisher) and a coverslip applied.

164

165 **2.4 Quantification of myotube thickness and nuclear fusion index**

166 24-well plates of immunofluorescence (IF) stained myotubes were imaged on an
167 epifluorescence/brightfield microscope (Leica DMI6000). Triplicate wells were
168 stimulated for each biological replicate and for each treatment condition. Multiple
169 images were taken in each well for the quantification of myotube thickness (MTT) and
170 nuclear fusion index (NFI). For quantification of MTT, 15 images per well were
171 obtained using a 63x objective, the first image being obtained at a fixed starting point
172 and subsequent images selected by moving to the next field of view in a predefined
173 pattern. For assessment of NFI, 5 images per well were obtained in the same fashion,
174 using a 20x objective. Image analysis was carried out by a blinded researcher, using
175 Image J software. A myotube was defined as a desmin positive structure, containing
176 3 or more nuclei. The MTT of each myotube was calculated by taking the average of
177 5 measurements obtained along its length. The NFI was defined as the number of
178 nuclei clearly incorporated into myotubes expressed as a proportion of the total visible
179 nuclei in each field of view.

180

181 **Immunoblotting**

182 Protein extraction, SDS-PAGE and immunoblotting were performed as previously
183 described (O'Leary et al. 2017). Primary antibodies for NFκB p65
184 (RRID:AB_10828935) (Cell Signalling Technology #6956), phosphorylated (Ser⁵³⁶)
185 NFκB p65 (RRID:AB_331284) (Cell Signalling Technology #3033) and resistin
186 (RRID:AB_326017) (polyclonal rabbit IgG, Thermo Fisher PA1-1049) were used. Anti-
187 mouse (RRID:AB_772210) (NA931V, GE Healthcare) and anti-rabbit
188 (RRID:AB_772206) (NA934, GE Healthcare) HRP-linked secondary antibodies were
189 diluted 1:5000 in TBS-T, and blots were developed using ECL-plus (GE Healthcare,

190 Amersham Biosciences, Amersham, UK) according to the manufacturer's instructions.
191 Bands were visualised on the ChemiDoc MP imaging system (Bio-Rad, UK).

192

193 **Immunoprecipitation of resistin from adipose conditioned media**

194 70 μ L Protein A Sepharose® beads (Abcam, ab193256) were incubated with 1 μ g
195 anti-resistin primary antibody (polyclonal rabbit IgG, Thermo Fisher PA1-1049) or 1 μ g
196 rabbit IgG isotype control (Sigma Aldrich, 12-370). The antibody-bead mixture was
197 incubated for 4 h at 4 °C on a shaker. The beads were centrifuged at 3,000 g for 2 min
198 at 4 °C and the supernatant was discarded. Beads were then washed twice with PBS,
199 5 mL ACM added to each bead-antibody conjugate and the ACM-bead-antibody
200 mixture incubated for 24 h at 4 °C with rotary agitation. The mixture was centrifuged
201 at 3,000 g for 2 min at 4 °C and the supernatant (ACM) was retained and stored at -
202 80 °C. The antibody-bead conjugates were washed in PBS as before. The antigen-
203 antibody complexes were eluted from the sepharose beads by the addition of 50 μ L
204 2x Laemmli sample loading buffer. The elutes were incubated at 50 °C for 10 min and
205 stored at – 80 °C in advance of their use in immunoblotting for the detection of resistin.

206

207 **Multiplex immunoassay**

208 Cytokine and chemokine concentrations were quantified in ACM secretome by
209 multiplex magnetic bead-based immunoassay (Luminex® Screening Assay, R&D
210 Systems) according to the manufacturer's instructions. 50 μ L of a 1x antibody
211 magnetic bead stock (Adiponectin, Serpin E1, Aggrecan, Amphiregulin, CCL11,
212 CCL2, CCL3, CCL20, Chemerin, CXCL10, Dkk1, Galectin-1, gp120, IL-1 β , IL-10, IL-
213 15, IL-7, visfatin, TNF α , Galectin-3BP, Lipocalin-2, CCL4, FABP4, LIF, Leptin, IL-6,
214 Resistin) was added to each well of a flat bottom black plate. 50 μ L of undiluted sample

215 or standard were added in duplicate to the plate. The plate was then sealed and
216 incubated for 2 h on an orbital rotator. The plate was washed three times with a
217 magnetic plate washer (Bio-Plex Pro™ Wash Station, Bio-Rad) using the wash buffer
218 provided. 50 µL of a biotinylated antibody cocktail was added to each well; the plate
219 was resealed and incubated for 1 h on the orbital rotator. The wash steps were
220 repeated as before and 50 µL of the provided streptavidin-PE was added to the wells.
221 The plate was incubated on the orbital rotator for 30 min and the wash steps repeated
222 for a final time. Finally, the beads were resuspended in 200 µL wash buffer and the
223 analytes were quantified by the Luminex® 200 multiplex analyser (Luminex®
224 Corporation).

225

226 **Statistical analysis**

227 Data analysis was carried out using IBM SPSS Statistics 21. All data are presented as
228 means ± SEM of biological replicates. The normality of data was established by a
229 Shapiro-Wilk test, whereas Levene's test was used to establish equality of variances.
230 For parametric data involving two treatment conditions unpaired t tests were used.
231 Non-parametric data were analysed by Mann-Whitney U tests. Where data involving
232 more than two treatment conditions were normally distributed, comparison was
233 performed by a one-way or two-way analysis of variance (ANOVA) with post-hoc
234 Bonferroni correction. Where such data were non-parametric, differences between
235 conditions were analysed by Mann-Whitney U test with post-hoc Holm's sequential
236 Bonferroni correction. A p value of < 0.05 was considered statistically significant.
237 Details of the statistical tests used for each data set can be found in the relevant figure
238 legend.

239 **Results**

240 **Quantification of adipokine in the secretome of subcutaneous adipose tissue**
241 **from lean and non-lean individuals**

242 We initially profiled the concentrations of 22 adipokines in SAT conditioned media
243 (ACM) collected from a cohort of normal weight (BMI<25, n=13) and overweight/obese
244 (BMI>25, n=22) older individuals by multiplex magnetic bead-based immunoassays
245 (Table 1).

246 Comparing the ACM from the 2 groups, there was no significant difference in the
247 concentration of the prominent adipokines leptin and adiponectin, the concentration of
248 well-known pro-inflammatory cytokines IL-1 β and IL-6, or in the concentration of the
249 anti-inflammatory cytokine IL-10. However, the mean concentration of resistin was
250 significantly greater ($p<0.05$) in the ACM from overweight/obese older individuals
251 (1778 ± 109 pg/mL) compared to the ACM collected from normal weight older
252 individuals (1207 ± 225 pg/mL). Furthermore, the median concentration of serpin E1
253 was significantly greater ($p<0.05$) in the ACM from overweight/obese (median =
254 10565, IQR = 3420-13450 pg/mL) compared to the ACM from normal weight older
255 individuals (median = 4156, IQR = 1337-6761 pg/mL). Of note, there was also a trend
256 for the median concentration of fatty acid binding protein 4 (FABP4) to be lower in
257 overweight/obese ACM compared to the normal weight, although this did not reach
258 significance (Table 1).

259

260 **Obese subcutaneous adipose tissue secretome impairs human myogenesis of**
261 **old, but not young, muscle cells**

262 Having determined the concentrations of adipokines secreted from lean and non-lean
263 SAT, we then sought to determine the effect of the ACM secretome derived from the

264 SAT of normal weight (NW, BMI < 25) and obese (OB, BMI > 30) individuals on
265 myotube formation. Subconfluent myoblasts from young and old lean, healthy subjects
266 (n = 3 per group) were switched to unconditioned differentiation medium, NW ACM or
267 OB ACM. Each young biological replicate was stimulated together with one from the
268 old experimental group such that both young and old replicates were stimulated with
269 the same NW and OB ACM sample. Media were renewed every 2 d. At 8 d, myotubes
270 were fixed, IF stained for desmin and DAPI and imaged on an epifluorescence
271 microscope (Fig. 1A).

272 Myotubes from elderly subjects that were stimulated with OB ACM were significantly
273 thinner ($30\% \pm 5\%$, $p = 0.009$) than their NW ACM counterparts (Fig. 1B). The NFI of
274 elderly myogenic cultures was also diminished ($42 \pm 6\%$, $p = 0.0003$) by OB ACM
275 compared to NW ACM (Fig. 1C). Young myotubes were not significantly affected by
276 stimulation with the same ACM samples, although a trend ($p = 0.09$) of reduced NFI
277 was observed when incubated with OB ACM (Fig. 1B, 1C).

278

279 **The adipokine resistin impairs human myogenesis**

280 Since the adipokine resistin was significantly elevated in the ACM of overweight/obese
281 individuals, we next examined the effect of stimulating myoblasts with recombinant
282 resistin during their differentiation to myotubes. Subconfluent myoblasts from young
283 (n = 3) and elderly (n = 3) subjects were switched to differentiation media or
284 differentiation media containing recombinant resistin (5 ng/mL). Media were renewed
285 every 2 d. At 8 d, cultures were fixed, IF stained for desmin and with DAPI, imaged on
286 an epifluorescence microscope and MTT and NFI were quantified as previously
287 described. Resistin significantly reduced MTT in both young ($18 \pm 5\%$, $p < 0.05$) and

288 old ($24 \pm 6 \%$, $p < 0.05$) myogenic cultures (Fig. 2A). NFI was significantly diminished
289 in old cultures only ($25 \pm 13 \%$, $p < 0.001$) (Fig. 2B).

290

291 **Depletion of resistin from obese subcutaneous adipose tissue secretome** 292 **improves myogenesis**

293 The effect of resistin on myogenesis was then validated by depletion of resistin from
294 OB ACM secretome by immunoprecipitation. Firstly, in order to confirm the success
295 of the immunoprecipitation, antibody conjugates were lysed and analysed by Western
296 blotting for the detection of bound resistin (Fig. 3A). Resistin was detected in the
297 resistin antibody conjugates lysates but not in the IgG control conjugate lysates (Fig.
298 3A). Secondly, the OB ACM was analysed before and after resistin
299 immunoprecipitation for the concentration of resistin by ELISA, employing a different
300 anti-resistin antibody than the immunoprecipitation procedure. Resistin concentrations
301 in OB ACM were diminished following resistin immunoprecipitation (Fig. 3B).

302 To examine the effect of resistin-depleted OB ACM secretome on myogenesis we
303 utilised commercially available primary human myoblasts, which we first validated as
304 responding in a similar way to our in-house cultures (Supplementary Figure 1).
305 Myoblasts were then switched to differentiation media containing either normal OB
306 ACM, or resistin-depleted OB ACM. Media was renewed every 2 days as previously
307 performed and myotubes fixed and stained at 8 days for the quantification of MTT and
308 NFI. Compared to normal OB ACM, myoblasts cultured with the resistin-depleted OB
309 ACM exhibited increased MTT of $53 \pm 13 \%$ ($p < 0.05$; Fig. 3C) and increased NFI of
310 $60 \pm 16 \%$ ($p < 0.05$; Fig. 3D).

311

312 **Resistin inhibits myogenesis by activation of the classical NF κ B pathway**

313 Classical NFκB pathway signalling is a negative regulator of myogenesis (Bakkar, et
314 al. 2008; Lu, et al. 2012). Furthermore, in multiple cells types, resistin has been shown
315 to activate NFκB signalling (Calabro, et al. 2011; Zhou, et al. 2013; Zuniga, et al. 2017).
316 Therefore, we next investigated whether the resistin-mediated effects on myogenesis
317 were *via* NFκB activation.

318 Myogenic cultures differentiated for 48 h in the presence of 5 ng/mL recombinant
319 resistin displayed a significant increase in serine⁵³⁶ phosphorylation of p65 (p-p65);
320 such phosphorylation was inhibited by the presence of the IKKβ inhibitor 5-(p-
321 Fluorophenyl)-2-ureido]thiophene-3-carboxamide (TPCA-1) (Fig. 4A, 4B). Having
322 established that resistin activates the classical NFκB signalling pathway during
323 myogenesis, the ability of TPCA-1 to rescue myotubes from the anti-myogenic actions
324 of resistin was explored. As before, 8 d resistin stimulation of differentiating myogenic
325 cultures significantly diminished MTT and NFI, a phenomenon that was completely
326 reversed by co-incubation with TPCA-1 (Fig. 4C, 4D).

327

328 **Discussion**

329 In this study, we describe for the first time the adverse myogenic effects of the obese
330 human SAT secretome, generated using conditioned media. The stromal vascular
331 fraction of adipose tissue is a more prolific secretor of pro-inflammatory cytokines than
332 mature adipocytes (Blaber et al. 2012) and thus our experimental model may be a
333 more physiologically relevant model of adipose tissue adipokine secretion than models
334 which rely upon adipokine secretion by adipocytes alone (Pellegrinelli et al. 2015).
335 Furthermore, since SAT represents a much larger proportion of total adipose tissue
336 mass than VAT (Isaac et al. 2011; Rosqvist et al. 2017; Rossi et al. 2011), its
337 contribution to the systemic inflammatory burden to which skeletal muscle is exposed
338 is likely to be significant. Indeed, myotubes from elderly subjects cultured with obese
339 SAT secretome were 30% thinner and had a 40% reduction in the number of nuclei
340 incorporated into myotubes, compared to those cultured with normal weight SAT
341 conditioned media. Previous work by Pellegrinelli et al. demonstrated that the lean
342 subcutaneous adipocyte inflammatory secretome does not have a detrimental effect
343 on myotube formation in neonatal myogenic cultures, but that the obese VAT adipocyte
344 secretome does inhibit myotube formation in such cultures (Pellegrinelli et al. 2015).
345 Interestingly, adipocytes isolated from obese SAT showed an intermediary negative
346 effect on MTT between lean SAT and obese VAT (Pellegrinelli et al. 2015). Our work
347 builds on these observations by the inclusion of both lean and obese SAT inflammatory
348 milieu, using whole adipose tissue rather than adipocytes to generate conditioned
349 medium and by demonstrating an anti-myogenic effect of OB ACM on elderly (but not
350 young) adult human myogenic cultures. Our results suggest that younger skeletal
351 muscle may be intrinsically more resilient to inflammatory cytokines secreted from
352 SAT.

353 In considering potential secretory factors that could be - at least in part - responsible
354 for the effect of the obese SAT secretome on myogenesis, the concentration of resistin
355 was found to be significantly elevated in the SAT conditioned media secretome
356 collected from non-lean (BMI > 25) older individuals, compared to that collected from
357 lean (BMI < 25) older individuals. Resistin is a pro-inflammatory adipokine that is
358 produced predominantly by monocytes and macrophages in humans, with a smaller
359 proportion being produced by adipocytes (Savage, et al. 2001). Given the importance
360 of adipose tissue M1 macrophage accumulation in ageing and obesity (Cancello, et
361 al. 2005; Fujisaka, et al. 2009; Lumeng, et al. 2007; Weisberg, et al. 2003), adipose
362 tissue secretion of resistin may be of significant consequence in sarcopenia. However,
363 few studies have previously described the effect of resistin on human skeletal muscle
364 and sarcopenia. Plasma resistin concentrations have been reported to have an inverse
365 relationship with quadriceps torque in old (69-81 yr), but not in young (18-30 yr),
366 subjects (Bucci et al. 2013). A recent study has described an inverse relationship
367 between abdominal skeletal muscle density and systemic resistin concentrations (Van
368 Hollebeke, et al. 2018); such increases in skeletal muscle density are thought to
369 indicate improved muscle quality and have been associated with increased muscle
370 strength (Goodpaster, et al. 2001). Furthermore, C2C12 mouse myoblast proliferation
371 is increased by the transfection of a human resistin eukaryotic expression vector, and
372 such transfection reduces the expression of desmin and results in thinner myotubes
373 (Sheng, et al. 2013). We thus identified resistin as warranting further exploration of its
374 myogenic effects.

375 Here, we demonstrate that stimulation of developing myotubes with recombinant
376 resistin, at a concentration reported physiologically in older humans (Philp et al. 2017),
377 has a substantial detrimental effect on the formation of such myotubes. Notably,

378 myogenic cultures from both young and old subjects were thinner following resistin
379 stimulation, but only old myotubes displayed a reduction in their NFI. Similarly, obese
380 SAT conditioned media that contained more resistin had a greater detrimental effect
381 on both myotube thickness and NFI of elderly myotubes compared to young myotubes.
382 This might indicate that there are age-related differences in the *ex vivo* myogenic
383 capacity of myoblasts under inflammatory conditions, with young muscle being more
384 resistant to pathological levels of adipokines such as resistin than older muscle. The
385 mechanisms underlying the differential responses of young and elderly myotubes to
386 OB ACM were not explored in this study, yet plausible avenues of enquiry exist.
387 Primary human myogenic cultures are known to retain some of the characteristics of
388 their donors (McAinch, et al. 2006; Mott, et al. 2000; Thompson, et al. 1996).
389 Furthermore, aged skeletal muscle displays increased classical NFκB pathway activity
390 (Buford and Manini 2010; Tilstra, et al. 2011). It is possible altered cytokine receptor
391 expression levels leave elderly myogenic cultures more susceptible to the detrimental
392 effects of OB ACM on culture differentiation. However, we are unaware of any
393 comprehensive profile of cytokine receptor gene or protein expression comparing
394 young and old human skeletal muscle.

395 Given these findings, it is highly significant that depletion of resistin from obese SAT
396 secretome completely abrogated the anti-myogenic action of obese SAT conditioned
397 media secretome. However, it is important to note that there are likely to be additional
398 factors within obese SAT conditioned media, which we did not assess, that could have
399 contributed to the considerable declines in both myotube thickness and NFI we
400 observed in elderly myotube cultures.

401 It is clear from the literature that resistin activates NFκB signaling. Such activation has
402 been demonstrated in the HepG2 cells (Zhou et al. 2013), human coronary artery

403 endothelial cells (Calabro et al. 2011) and in human macrophages (Zuniga et al. 2017).
404 Importantly, genetic approaches have now established the classical NF κ B pathway as
405 a negative regulator of myogenesis. Myogenesis has been shown to be enhanced in
406 p65^{-/-} myoblasts (Bakkar et al. 2008), whilst the IKK β inhibitor IV has been shown to
407 enhance the myogenic differentiation of primary murine cultures from wild-type mice
408 (Lu et al. 2012). Furthermore, NF κ B activation in the satellite cells of aged mice
409 inhibited skeletal muscle regeneration in response to cryoinjury (Oh, et al. 2016).
410 In myogenic cultures, classical NF κ B pathway activity is diminished at 48 h post-
411 differentiation (Bakkar et al. 2008). Importantly, we observed that the addition of
412 recombinant resistin to our myogenic cultures resulted in persistent p65
413 phosphorylation (indicative of NF κ B activation) at 48 h, a phenomenon that was
414 reversed by the addition of the IKK2 inhibitor TPCA-1. Importantly, TPCA-1 rescued
415 the differentiation of our myogenic cultures in the presence of recombinant resistin,
416 suggesting therefore that resistin impaired myogenesis *via* activation of the classical
417 NF κ B pathway.

418

419 In summary, our studies describe a detrimental effect of obese SAT conditioned media
420 secretome on primary human myogenesis and identify resistin as the adipokine that -
421 at least in part - mediates this effect. Furthermore, we demonstrate that resistin exerts
422 its anti-myogenic effects by causing persistent activation of the classical NF κ B
423 pathway. These findings may have important implications for the maintenance of
424 muscle mass in older people who are obese or overweight, or those with chronic
425 conditions such as osteoarthritis (Philp et al. 2017) and type 2 diabetes (Gharibeh, et
426 al. 2010), which are associated with increased levels of resistin in the circulation.

427

428 **Declaration of Interest:** No conflict of interest.

429 **Funding:** Mary O’Leary was supported by a Wellcome Trust PhD Studentship
430 (102284/Z/13/Z). The funder had no role in the study design; in the collection,
431 analysis and interpretation of data; in the writing of the report; and in the decision to
432 submit the article for publication.

433 **Author Contributions:** MOL conceived, designed, performed the experiments,
434 analysed the data and wrote the article. KT, GW and SJ conceived and designed the
435 experiments and wrote the article. AB and ED conceived and designed the
436 experiments.

437 **Acknowledgements**

438 We thank all the subjects who participated in this study. We acknowledge and
439 appreciate Research Nurse support at The Royal Orthopaedic Hospital NHS
440 Foundation Trust (Laura Bird, and Hannah Spencer) and at Russells Hall Hospital
441 (Elise Cooke). We also acknowledge and appreciate the support from all staff in the
442 David Greenfield Human Physiology Unit at the University of Nottingham. We also
443 thank the surgeons, Mr. Matthew Revell, Mr. David Dunlop, Mr. Andrew Pearson and
444 Mr. Sohail Quraishi who facilitated this work. The authors Dr Jones and Dr Tsintzas
445 contributed equally to this work.

446

447

448

449

450

451

452

453

454

455 **References**

- 456 Adams V, Mangner N, Gasch A, Krohne C, Gielen S, Hirner S, Thierse HJ, Witt CC, Linke A, Schuler G,
457 et al. 2008 Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. *J*
458 *Mol Biol* **384** 48-59.
- 459 Akhmedov D & Berdeaux R 2013 The effects of obesity on skeletal muscle regeneration. *Front*
460 *Physiol* **4** 371.
- 461 Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, Acharyya S, Rudnicki MA,
462 Hollenbach AD & Guttridge DC 2008 IKK/NF-kappaB regulates skeletal myogenesis via a signaling
463 switch to inhibit differentiation and promote mitochondrial biogenesis. *J Cell Biol* **180** 787-802.
- 464 Batsis JA, Mackenzie TA, Jones JD, Lopez-Jimenez F & Bartels SJ 2016 Sarcopenia, sarcopenic obesity
465 and inflammation: Results from the 1999-2004 National Health and Nutrition Examination Survey.
466 *Clin Nutr* **35** 1472-1483.
- 467 Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D & Morley JE 2004 Sarcopenic obesity
468 predicts instrumental activities of daily living disability in the elderly. *Obes Res* **12** 1995-2004.
- 469 Blaber SP, Webster RA, Hill CJ, Breen EJ, Kuah D, Vesey G & Herbert BR 2012 Analysis of in vitro
470 secretion profiles from adipose-derived cell populations. *J Transl Med* **10** 172.
- 471 Bucci L, Yani SL, Fabbri C, Bijlsma AY, Maier AB, Meskers CG, Narici MV, Jones DA, McPhee JS, Seppet
472 E, et al. 2013 Circulating levels of adipokines and IGF-1 are associated with skeletal muscle strength
473 of young and old healthy subjects. *Biogerontology* **14** 261-272.
- 474 Buford TW & Manini TM 2010 Sedentary individuals as "controls" in human studies: the correct
475 approach? *Proc Natl Acad Sci U S A* **107** E134.
- 476 Calabro P, Cirillo P, Limongelli G, Maddaloni V, Riegler L, Palmieri R, Pacileo G, De Rosa S, Pacileo M,
477 De Palma R, et al. 2011 Tissue factor is induced by resistin in human coronary artery endothelial cells
478 by the NF-kB-dependent pathway. *J Vasc Res* **48** 59-66.
- 479 Canello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D,
480 Bouillot JL, et al. 2005 Reduction of macrophage infiltration and chemoattractant gene expression
481 changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss.
482 *Diabetes* **54** 2277-2286.
- 483 Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, Tsuneyama K, Nagai Y, Takatsu K, Urakaze
484 M, et al. 2009 Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced
485 obese mice. *Diabetes* **58** 2574-2582.
- 486 Garcia-Martinez C, Agell N, Llovera M, Lopez-Soriano FJ & Argiles JM 1993 Tumour necrosis factor-
487 alpha increases the ubiquitination of rat skeletal muscle proteins. *FEBS Lett* **323** 211-214.
- 488 Garcia-Martinez C, Llovera M, Agell N, Lopez-Soriano FJ & Argiles JM 1994 Ubiquitin gene expression
489 in skeletal muscle is increased by tumour necrosis factor-alpha. *Biochem Biophys Res Commun* **201**
490 682-686.
- 491 Gharibeh MY, Al Tawallbeh GM, Abboud MM, Radaideh A, Alhader AA & Khabour OF 2010
492 Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. *Diabetes*
493 *Metab* **36** 443-449.
- 494 Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm E & Newman AB
495 2001 Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. *J Appl Physiol*
496 (1985) **90** 2157-2165.
- 497 Haddad F, Zaldivar F, Cooper DM & Adams GR 2005 IL-6-induced skeletal muscle atrophy. *J Appl*
498 *Physiol* (1985) **98** 911-917.
- 499 Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Gedrich K & Pollmacher T 2006
500 TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. *Eur*
501 *Cytokine Netw* **17** 196-201.
- 502 Isaac V, Sim S, Zheng H, Zagorodnov V, Tai ES & Chee M 2011 Adverse Associations between Visceral
503 Adiposity, Brain Structure, and Cognitive Performance in Healthy Elderly. *Front Aging Neurosci* **3** 12.

504 Jonas MI, Kurylowicz A, Bartoszewicz Z, Lisik W, Jonas M, Domienik-Karlowicz J & Puzianowska-
505 Kuznicka M 2017 Adiponectin/resistin interplay in serum and in adipose tissue of obese and normal-
506 weight individuals. *Diabetol Metab Syndr* **9** 95.

507 Kyle UG, Genton L, Hans D, Karsegard VL, Michel JP, Slosman DO & Pichard C 2001 Total body mass,
508 fat mass, fat-free mass, and skeletal muscle in older people: cross-sectional differences in 60-year-
509 old persons. *J Am Geriatr Soc* **49** 1633-1640.

510 Lehr S, Hartwig S & Sell H 2012 Adipokines: a treasure trove for the discovery of biomarkers for
511 metabolic disorders. *Proteomics Clin Appl* **6** 91-101.

512 Lu A, Proto JD, Guo L, Tang Y, Lavasani M, Tilstra JS, Niedernhofer LJ, Wang B, Guttridge DC, Robbins
513 PD, et al. 2012 NF-kappaB negatively impacts the myogenic potential of muscle-derived stem cells.
514 *Mol Ther* **20** 661-668.

515 Lumeng CN, Bodzin JL & Saltiel AR 2007 Obesity induces a phenotypic switch in adipose tissue
516 macrophage polarization. *J Clin Invest* **117** 175-184.

517 McAinch AJ, Steinberg GR, Mollica J, O'Brien PE, Dixon JB, Macaulay SL, Kemp BE & Cameron-Smith D
518 2006 Differential regulation of adiponectin receptor gene expression by adiponectin and leptin in
519 myotubes derived from obese and diabetic individuals. *Obesity (Silver Spring)* **14** 1898-1904.

520 Mott DM, Hoyt C, Caspari R, Stone K, Pratley R & Bogardus C 2000 Palmitate oxidation rate and
521 action on glycogen synthase in myoblasts from insulin-resistant subjects. *Am J Physiol Endocrinol*
522 *Metab* **279** E561-569.

523 O'Leary MF, Wallace GR, Bennett AJ, Tsintzas K & Jones SW 2017 IL-15 promotes human myogenesis
524 and mitigates the detrimental effects of TNFalpha on myotube development. *Sci Rep* **7** 12997.

525 Oh J, Sinha I, Tan KY, Rosner B, Dreyfuss JM, Gjata O, Tran P, Shoelson SE & Wagers AJ 2016 Age-
526 associated NF-kappaB signaling in myofibers alters the satellite cell niche and re-strains muscle stem
527 cell function. *Aging (Albany NY)* **8** 2871-2896.

528 Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, Albert V, Edom-Vovard F, Vidal-Puig A, Clement K,
529 Butler-Browne GS & Lacasa D 2015 Human Adipocytes Induce Inflammation and Atrophy in Muscle
530 Cells During Obesity. *Diabetes* **64** 3121-3134.

531 Philp AM, Collier RL, Grover LM, Davis ET & Jones SW 2017 Resistin promotes the abnormal Type I
532 collagen phenotype of subchondral bone in obese patients with end stage hip osteoarthritis. *Sci Rep*
533 **7** 4042.

534 Rosqvist F, Bjermo H, Kullberg J, Johansson L, Michaelsson K, Ahlstrom H, Lind L & Riserus U 2017
535 Fatty acid composition in serum cholesterol esters and phospholipids is linked to visceral and
536 subcutaneous adipose tissue content in elderly individuals: a cross-sectional study. *Lipids Health Dis*
537 **16** 68.

538 Rossi AP, Watson NL, Newman AB, Harris TB, Kritchevsky SB, Bauer DC, Satterfield S, Goodpaster BH
539 & Zamboni M 2011 Effects of body composition and adipose tissue distribution on respiratory
540 function in elderly men and women: the health, aging, and body composition study. *J Gerontol A Biol*
541 *Sci Med Sci* **66** 801-808.

542 RRID:AB_326017.

543 RRID:AB_331284.

544 RRID:AB_772206.

545 RRID:AB_772210.

546 RRID:AB_10828935.

547 Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV & O'Rahilly S 2001 Resistin /
548 Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action
549 in humans. *Diabetes* **50** 2199-2202.

550 Schautz B, Later W, Heller M, Muller MJ & Bosy-Westphal A 2012 Total and regional relationship
551 between lean and fat mass with increasing adiposity--impact for the diagnosis of sarcopenic obesity.
552 *Eur J Clin Nutr* **66** 1356-1361.

553 Sheng CH, Du ZW, Song Y, Wu XD, Zhang YC, Wu M, Wang Q & Zhang GZ 2013 Human resistin
554 inhibits myogenic differentiation and induces insulin resistance in myocytes. *Biomed Res Int* **2013**
555 804632.

556 Skurk T, Alberti-Huber C, Herder C & Hauner H 2007 Relationship between adipocyte size and
557 adipokine expression and secretion. *J Clin Endocrinol Metab* **92** 1023-1033.

558 Srikanthan P, Hevener AL & Karlamangla AS 2010 Sarcopenia exacerbates obesity-associated insulin
559 resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III.
560 *PLoS One* **5** e10805.

561 Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB & Ferrucci L 2008 Sarcopenic obesity:
562 definition, cause and consequences. *Curr Opin Clin Nutr Metab Care* **11** 693-700.

563 Takegahara Y, Yamanouchi K, Nakamura K, Nakano S & Nishihara M 2014 Myotube formation is
564 affected by adipogenic lineage cells in a cell-to-cell contact-independent manner. *Exp Cell Res* **324**
565 105-114.

566 Thompson DB, Pratley R & Ossowski V 1996 Human primary myoblast cell cultures from non-diabetic
567 insulin resistant subjects retain defects in insulin action. *J Clin Invest* **98** 2346-2350.

568 Tilstra JS, Clauson CL, Niedernhofer LJ & Robbins PD 2011 NF-kappaB in Aging and Disease. *Aging Dis*
569 **2** 449-465.

570 Tsujinaka T, Ebisui C, Fujita J, Kishibuchi M, Morimoto T, Ogawa A, Katsume A, Ohsugi Y, Kominami E
571 & Monden M 1995 Muscle undergoes atrophy in association with increase of lysosomal cathepsin
572 activity in interleukin-6 transgenic mouse. *Biochem Biophys Res Commun* **207** 168-174.

573 Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki
574 H, et al. 1996 Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic
575 systems in interleukin 6 transgenic mice. *J Clin Invest* **97** 244-249.

576 Van Hollebeke RB, Cushman M, Schlueter EF & Allison MA 2018 Abdominal Muscle Density is
577 Inversely Related to Adiposity Inflammatory Mediators. *Med Sci Sports Exerc*.

578 Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M & Harris TB
579 2002 Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle
580 strength in elderly men and women: the Health ABC Study. *J Gerontol A Biol Sci Med Sci* **57** M326-
581 332.

582 Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL & Ferrante AW, Jr. 2003 Obesity is
583 associated with macrophage accumulation in adipose tissue. *J Clin Invest* **112** 1796-1808.

584 Yamada M, Moriguchi Y, Mitani T, Aoyama T & Arai H 2014 Age-dependent changes in skeletal
585 muscle mass and visceral fat area in Japanese adults from 40 to 79 years-of-age. *Geriatr Gerontol Int*
586 **14 Suppl 1** 8-14.

587 Zhou L, Yu X, Meng Q, Li H, Niu C, Jiang Y, Cai Y, Li M, Li Q, An C, et al. 2013 Resistin reduces
588 mitochondria and induces hepatic steatosis in mice by the protein kinase C/protein kinase
589 G/p65/PPAR gamma coactivator 1 alpha pathway. *Hepatology* **57** 1384-1393.

590 Zuniga MC, Raghuraman G, Hitchner E, Weyand C, Robinson W & Zhou W 2017 PKC-epsilon and TLR4
591 synergistically regulate resistin-mediated inflammation in human macrophages. *Atherosclerosis* **259**
592 51-59.

593

594 **Figure 1. Obese subcutaneous adipose conditioned medium inhibits myotube**
595 **formation in differentiating human myoblasts.**

596 Subconfluent myoblasts were switched to unconditioned differentiation medium or
597 differentiation medium that had previously been conditioned with adipose tissue from
598 normal weight (NW ACM, n = 3; BMI<25 kg/m²) or obese individuals (OB ACM, n =
599 3; BMI>30 kg/m²). Each young (18-30 yr) biological replicate was paired with one from
600 the old (> 65 yr) experimental group, with both being stimulated with the same ACM
601 samples. Media were renewed every 2 d. At 8 d, myotubes were fixed,
602 immunofluorescence stained for desmin and with DAPI and imaged on an
603 epifluorescence microscope. **(A)** Representative images at 20x magnification. **(B)**
604 Myotube thickness data represent the mean ± SEM of n = 3 biological replicates. Each
605 biological replicate comprises 150 total measurements taken at 63x magnification from
606 30 myotubes per treatment condition. **(C)** Nuclear fusion index data are expressed as
607 mean ± SEM values of n = 3 biological replicates. Each biological replicate comprises
608 15 images taken at 20x magnification. **p < 0.01, ***p < 0.001 by Mann-Whitney U
609 test with post-hoc Holm's sequential Bonferroni adjustment.

610

611 **Figure 2. Recombinant resistin impairs myotube formation in myotubes derived**
612 **from young and elderly subjects.**

613 Subconfluent myoblasts from young and elderly subjects were switched to
614 differentiation media (with or without 5 ng/mL recombinant resistin). Media were
615 renewed every 2 d. At 8 d, myotubes were fixed, immunofluorescence stained for
616 desmin and with DAPI and imaged on an epifluorescence microscope. **(A)** Myotube
617 thickness data represent the mean ± SEM of n = 3 biological replicates. Each biological
618 replicate comprises 150 total measurements taken at 63x magnification from 30

619 myotubes per treatment condition. **(B)** Nuclear fusion index data are expressed as
620 mean \pm SEM values of n = 3 biological replicates. Each biological replicate comprises
621 15 images taken at 20x magnification. *p < 0.05, ***p < 0.001 by unpaired t test.

622

623 **Figure 3. Immunoprecipitation of resistin from obese subcutaneous adipose**
624 **conditioned medium secretome (OB ACM) improves myogenesis.**

625 Resistin was immunoprecipitated from OB ACM using resistin antibody-agarose bead
626 conjugates (OB ACM – resistin IP). IgG isotype antibody control-agarose bead
627 conjugates were used on the same samples as a control (OB ACM). **(A)** Resistin
628 protein is detected by immunoblotting of resistin-antibody lysates but not IgG control
629 lysates following immunoprecipitation. **(B)** Depletion of resistin in OB ACM following
630 resistin immunoprecipitation as determined by ELISA. **(C)** Subconfluent, commercially
631 available primary human skeletal myoblasts from a female aged 21 yr were switched
632 to either OB ACM differentiation media (OB ACM, n =4) or to resistin-depleted OB
633 ACM differentiation media (OB ACM Resistin IP, n = 4). Media were renewed every 2
634 d. At 8 d, myotubes were fixed, immunofluorescence stained for desmin and with DAPI
635 and imaged on an epifluorescence microscope. Nuclear fusion index data are
636 expressed as mean \pm SEM values of n = 3 independent experiments. Each
637 independent experiment comprises 15 images taken at 20x magnification. **(D)** Myotube
638 thickness data represent the mean \pm SEM of n = 3 independent experiments. Each
639 independent experiment comprises 150 total measurements taken at 63x
640 magnification from 30 myotubes per treatment condition. *p < 0.05 vs OB ACM by
641 unpaired t test.

642

643 **Figure 4. Resistin exerts its anti-myogenic effects via activation of the classical**
644 **NFκB pathway.**

645 **(A, B)** Subconfluent primary human skeletal myoblasts from a female aged 21 yr were
646 switched to differentiation media (with or without 5 ng/mL recombinant resistin ± 40
647 nM TPCA-1) for 48 h. Phospho-p65 (Ser536) and total p65 were detected by
648 immunoblotting. US = unstimulated, R = resistin, T = TPCA-1, RT = resistin + TPCA-
649 1. Data are expressed as mean ± SEM values of n = 3 independent experiments. **p
650 < 0.01 by one-way ANOVA with post-hoc Bonferroni correction. **(C, D)** Subconfluent
651 primary human skeletal myoblasts from a female aged 21 yr were switched to
652 differentiation media (with or without 5 ng/mL recombinant resistin ± 40 nM TPCA-1).
653 Media were renewed every 2 d. At 8 d, myotubes were fixed, immunofluorescence
654 stained for desmin and with DAPI and imaged on an epifluorescence microscope.
655 Myotube thickness data represents the mean ± SEM of n = 3 independent
656 experiments. Each independent experiment comprises 150 total measurements taken
657 at 63x magnification from 30 myotubes per treatment condition. Nuclear fusion index
658 data are expressed as mean ± SEM values of n = 3 independent experiments. Each
659 independent experiment comprises 15 images taken at 20x magnification. **p < 0.01,
660 ***p < 0.001 vs unstimulated control by Mann-Whitney U test with post-hoc Holm's
661 sequential Bonferroni adjustment.

662

663

664

Table 1. The Inflammatory Secretory Profile of Normal weight (Lean) and overweight/obese (non-Lean) Subcutaneous Adipose Conditioned Medium

	Lean (BMI < 25) (Mean ± SEM, pg/mL)	Non-Lean (BMI > 25) (Mean ± SEM, pg/mL)	P-value (Lean vs. non-lean)
Adiponectin	28716 ± 4524	28841 ± 3779	0.18
Aggrecan	578, 559-606	530, 468-567	0.07 [¶]
Amphiregulin	532 ± 137	703 ± 67	0.22
Chemerin-1	2655 ± 673	3450 ± 583	0.44
Eotaxin	95 ± 41	61 ± 12	0.81
FABP4	38x10 ⁴ , 27x10 ⁴ -81x10 ⁴	27 x10 ⁴ , 23 x10 ⁴ -39 x10 ⁴	0.06 [¶]
Galectin-1	5.3 x10 ⁴ ± 0.6 x10 ⁴	5.2 x10 ⁴ ± 0.3 x10 ⁴	0.85
GP130	29001 ± 10480	31824 ± 7342	0.83
IL-10	2.25 ± 0.56	2.59 ± 0.39	0.62
IL-15	1.81 ± 0.52	2.32 ± 0.37	0.45
IL-1β	12.02 ± 1.59	11.94 ± 1	0.96
IL-6	507, 436-1044	1528, 719-2889	0.12 [¶]
IL-7	3.02 ± 0.27	3.04 ± 0.29	0.96
Leptin	11335 ± 2592	12210 ± 2467	0.83
MCP-1	2372 ± 924	1540 ± 406	0.34
MIP1a	363 ± 54	303 ± 32	0.33
MIP1b	101 ± 37	125 ± 24	0.58
MIP3a	85 ± 25	164 ± 51	0.97
Resistin	1207 ± 225	1778 ± 109	0.01
Serpin E1	4156, 1337-6761	10565, 3420-13450	0.02 [¶]
TNFα	10.43 ± 1.57	10.43 ± 1.17	0.99
Visfatin	114, 1007-1827	917, 2051-2417	0.91 [¶]

Adipokine concentrations were determined by multiplex magnetic bead-based cytokine assays in ACM from lean (BMI < 25, n = 13) and non-lean (BMI > 25, n = 22) subjects. Data are presented as mean ± SEM where normally distributed and as median, 25th percentile-75th percentile where not normally distributed (marked [¶]). FABP4= Fatty acid binding protein 4, GP130=glycoprotein 130, MCP-1=Monocyte chemoattractant protein 1, MIP1a=Macrophage inflammatory protein 1a, MIP1b=Macrophage inflammatory protein 1b, MIP3a=Macrophage inflammatory protein 3a. IL=Interleukin; TNFα=Tumor Necrosis Factor alpha.

665

666



667

668



669

670



A



B







C





672

673

674




675




676


A



B



C



D

